Skip to main content
Erschienen in: Calcified Tissue International 1/2006

01.01.2006

Serum Levels of Insulin-Like Growth Factor (IGF); IGF-Binding Proteins-3, -4, and -5; and Their Relationships to Bone Mineral Density and the Risk of Vertebral Fractures in Postmenopausal Women

verfasst von: T. Yamaguchi, M. Kanatani, M. Yamauchi, H. Kaji, T. Sugishita, D. J. Baylink, S. Mohan, K. Chihara, T. Sugimoto

Erschienen in: Calcified Tissue International | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

We previously found that serum levels of insulin-like growth factor I (IGF-I) and IGF-binding protein (IGFBP)-3, but not IFGBP-2, were associated with bone mineral density (BMD) and the risk of vertebral fractures. The aim of the present study was to investigate the roles of IGFBP-4 and -5 in age-dependent bone loss and vertebral fracture risk in postmenopausal Japanese women and to compare them with those of IGF-I and IGFBP-3. One hundred and ninety-three Japanese women aged 46–88 years (mean 62.5) were enrolled in the cross-sectional study. BMD was measured at the lumbar spine, femoral neck, ultradistal radius (UDR), and total body by dual-energy X-ray absorptiometry. Serum levels of IGFBP-4 and -5 as well as IGF-I and IGFBP-3 were measured by radioimmunoassay. Serum levels of IGF-I, IGFBP-3, and IGFBP-5 declined with age, while serum IGFBP-4 increased with age. Multiple regression analysis was performed between BMD at each skeletal site and serum levels of IGF-I and IGFBPs adjusted for age, body weight, height, and serum creatinine. BMD at the UDR was significantly and positively correlated with all serum levels of IGF-I and IGFBPs measured (P < 0.01), while BMD at the femoral neck was correlated with none of them. Serum IGF-I level was significantly and positively correlated with BMD at all sites except the femoral neck (P < 0.01), while serum IGFBP-3 and -4 levels were significantly and positively correlated with only radial BMD (P < 0.01). Serum IGFBP-5 level was positively correlated with UDR BMD (P < 0.001) and negatively correlated with total BMD (P < 0.05). Serum IGF-I, IGFBP-3, and IFGBP-5 levels were significantly lower in women with vertebral fractures than in those without fractures (mean ± SD: 97.1 ± 32.1 vs. 143.9 ± 40.9 ng/dl, P < 0.0001; 2.18 ± 1.02 vs. 3.23 ± 1.07 μg/ml, P < 0.0001; 223.6 ± 63.3 vs. 246.5 ± 71.5 ng/ml, P = 0.0330, respectively). When multivariate logistic regression analysis was performed with the presence of vertebral fractures as a dependent variable and serum levels of IGF-I and IGFBPs adjusted for age, body weight, height, serum creatinine, and serum alubumin as independent variables, IGF-I and IGFBP-3 were selected as indices affecting the presence of vertebral fractures [odds ratio (OR) = 0.29, 95% confidential interval (CI) 0.15–0.57 per SD increase, P = 0.0003 and OR = 0.31, 95% CI 0.16–0.61 per SD increase, P = 0.0007, respectively]. To compare the significance values, IGF-I, IGFBP-3, and age were simultaneously added as independent variables in the analysis. IGFBP-3 was more strongly associated with the presence of vertebral fractures than IGF-I and age (P = 0.0006, P = 0.0148, and P = 0.0013, respectively). Thus, after comprehensive measurements of serum levels of IGF-I and IGFBPs, it seems that serum IGF-I level is most efficiently associated with bone mass and that serum IGFBP-3 level is most strongly associated with the presence of vertebral fractures in postmenopausal women among the IGF system components examined.
Literatur
1.
2.
Zurück zum Zitat Mohan S, Baylink DJ (1991) Bone growth factors. Clin Orthop Relat Res 263:30–48PubMed Mohan S, Baylink DJ (1991) Bone growth factors. Clin Orthop Relat Res 263:30–48PubMed
3.
Zurück zum Zitat McCarthy TL, Centrella M, Canalis E (1989) Insulin-like growth factor (IGF) and bone. Connect Tissue Res 20:277–282PubMed McCarthy TL, Centrella M, Canalis E (1989) Insulin-like growth factor (IGF) and bone. Connect Tissue Res 20:277–282PubMed
4.
Zurück zum Zitat Mohan S (1993) Insulin-like growth factor binding proteins in bone cell regulation. Growth Regul 3:67–70PubMed Mohan S (1993) Insulin-like growth factor binding proteins in bone cell regulation. Growth Regul 3:67–70PubMed
5.
Zurück zum Zitat Johansson AG, Lindh E, Ljunghall S (1992) Insulin-like growth factor I stimulates bone turnover in osteoporosis. Lancet 339:1619CrossRefPubMed Johansson AG, Lindh E, Ljunghall S (1992) Insulin-like growth factor I stimulates bone turnover in osteoporosis. Lancet 339:1619CrossRefPubMed
6.
Zurück zum Zitat Schwander JC, Hauri C, Zapf J, Froesch ER (1983) Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 113:297–305PubMed Schwander JC, Hauri C, Zapf J, Froesch ER (1983) Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 113:297–305PubMed
7.
Zurück zum Zitat Spencer EM, Liu CC, Si EC, Howard GA (1991) In vivo actions of insulin-like growth factor-I (IGF-I) on bone formation and resorption in rats. Bone 12:21–26CrossRefPubMed Spencer EM, Liu CC, Si EC, Howard GA (1991) In vivo actions of insulin-like growth factor-I (IGF-I) on bone formation and resorption in rats. Bone 12:21–26CrossRefPubMed
8.
Zurück zum Zitat Bing-You RG, Denis MC, Rosen CJ (1993) Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. Calcif Tissue Int 52:183–187CrossRefPubMed Bing-You RG, Denis MC, Rosen CJ (1993) Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. Calcif Tissue Int 52:183–187CrossRefPubMed
9.
Zurück zum Zitat Corpas E, Harman SM, Blackman MR (1993) Human growth hormone and human aging. Endocr Rev 14:20–39CrossRefPubMed Corpas E, Harman SM, Blackman MR (1993) Human growth hormone and human aging. Endocr Rev 14:20–39CrossRefPubMed
10.
Zurück zum Zitat Johansson AG, Forslund A, Hambraeus L, Blum WF, Ljunghall S (1994) Growth hormone-dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men. J Bone Miner Res 9:915–921PubMed Johansson AG, Forslund A, Hambraeus L, Blum WF, Ljunghall S (1994) Growth hormone-dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men. J Bone Miner Res 9:915–921PubMed
11.
Zurück zum Zitat Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34CrossRefPubMed Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34CrossRefPubMed
12.
Zurück zum Zitat Rajaram S, Baylink DJ, Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801–831CrossRefPubMed Rajaram S, Baylink DJ, Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801–831CrossRefPubMed
13.
Zurück zum Zitat Rechler MM (1993) Insulin-like growth factor-binding proteins. Vitam Horm 47:1–114PubMed Rechler MM (1993) Insulin-like growth factor-binding proteins. Vitam Horm 47:1–114PubMed
14.
Zurück zum Zitat Andress DL, Birnbaum RS (1992) Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem 267:22467–22472PubMed Andress DL, Birnbaum RS (1992) Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem 267:22467–22472PubMed
15.
Zurück zum Zitat Feyen JH, Evans DB, Binkert C, Heinrich GF, Geisse S, Kocher HP (1991) Recombinant human [Cys281]insulin-like growth factor-binding protein 2 inhibits both basal and insulin-like growth factor I-stimulated proliferation and collagen synthesis in fetal rat calvariae. J Biol Chem 266:19469–19474PubMed Feyen JH, Evans DB, Binkert C, Heinrich GF, Geisse S, Kocher HP (1991) Recombinant human [Cys281]insulin-like growth factor-binding protein 2 inhibits both basal and insulin-like growth factor I-stimulated proliferation and collagen synthesis in fetal rat calvariae. J Biol Chem 266:19469–19474PubMed
16.
Zurück zum Zitat Schiltz PM, Mohan S, Baylink DJ (1993) Insulin-like growth factor binding protein-4 inhibits both basal and IGF-mediated chick pelvic cartilage growth in vitro. J Bone Miner Res 8:391–396PubMed Schiltz PM, Mohan S, Baylink DJ (1993) Insulin-like growth factor binding protein-4 inhibits both basal and IGF-mediated chick pelvic cartilage growth in vitro. J Bone Miner Res 8:391–396PubMed
17.
Zurück zum Zitat Baxter RC (1993) Circulating binding proteins for the insulin-like growth factors. Trends Endocrinol Metab 4:91–96CrossRefPubMed Baxter RC (1993) Circulating binding proteins for the insulin-like growth factors. Trends Endocrinol Metab 4:91–96CrossRefPubMed
18.
Zurück zum Zitat Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR (1990) A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 70:1292–1298PubMedCrossRef Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR (1990) A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 70:1292–1298PubMedCrossRef
19.
Zurück zum Zitat Corpas E, Harman SM, Blackman MR (1992) Serum IGF-binding protein-3 is related to IGF-I, but not to spontaneous GH release, in healthy old men. Horm Metab Res 24:543–545PubMedCrossRef Corpas E, Harman SM, Blackman MR (1992) Serum IGF-binding protein-3 is related to IGF-I, but not to spontaneous GH release, in healthy old men. Horm Metab Res 24:543–545PubMedCrossRef
20.
Zurück zum Zitat Laron Z, Klinger B, Blum WF, Silbergeld A, Ranke MB (1992) IGF binding protein 3 in patients with Laron type dwarfism: effect of exogenous rIGF-I. Clin Endocrinol (Oxf) 36:301–304 Laron Z, Klinger B, Blum WF, Silbergeld A, Ranke MB (1992) IGF binding protein 3 in patients with Laron type dwarfism: effect of exogenous rIGF-I. Clin Endocrinol (Oxf) 36:301–304
21.
Zurück zum Zitat Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K (1997) Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 12:1272–1279PubMedCrossRef Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K (1997) Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 12:1272–1279PubMedCrossRef
22.
Zurück zum Zitat Mohan S, Bautista CM, Wergedal J, Baylink DJ (1989) Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: a potential local regulator of IGF action. Proc Natl Acad Sci USA 86:8338–8342PubMed Mohan S, Bautista CM, Wergedal J, Baylink DJ (1989) Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: a potential local regulator of IGF action. Proc Natl Acad Sci USA 86:8338–8342PubMed
23.
Zurück zum Zitat Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, Lang K, Baylink DJ (1995) Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem 270:20424–20431PubMedCrossRef Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, Lang K, Baylink DJ (1995) Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem 270:20424–20431PubMedCrossRef
24.
Zurück zum Zitat Albertsson-Wikland K, Hall K (1987) Growth hormone treatment in short children: relationship between growth and serum insulin-like growth factor I and II levels. J Clin Endocrinol Metab 65:671–678PubMed Albertsson-Wikland K, Hall K (1987) Growth hormone treatment in short children: relationship between growth and serum insulin-like growth factor I and II levels. J Clin Endocrinol Metab 65:671–678PubMed
25.
Zurück zum Zitat Daughaday WH, Mariz IK, Blethen SL (1980) Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab 51:781–788PubMed Daughaday WH, Mariz IK, Blethen SL (1980) Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab 51:781–788PubMed
26.
Zurück zum Zitat Honda Y, Landale EC, Strong DD, Baylink DJ, Mohan S (1996) Recombinant synthesis of insulin-like growth factor-binding protein-4 (IGFBP-4): development, validation, and application of a radioimmunoassay for IGFBP-4 in human serum and other biological fluids. J Clin Endocrinol Metab 81:1389–1396CrossRefPubMed Honda Y, Landale EC, Strong DD, Baylink DJ, Mohan S (1996) Recombinant synthesis of insulin-like growth factor-binding protein-4 (IGFBP-4): development, validation, and application of a radioimmunoassay for IGFBP-4 in human serum and other biological fluids. J Clin Endocrinol Metab 81:1389–1396CrossRefPubMed
27.
Zurück zum Zitat Mohan S, Libanati C, Dony C, Lang K, Srinivasan N, Baylink DJ (1995) Development, validation, and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids. J Clin Endocrinol Metab 80:2638–2645PubMedCrossRef Mohan S, Libanati C, Dony C, Lang K, Srinivasan N, Baylink DJ (1995) Development, validation, and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids. J Clin Endocrinol Metab 80:2638–2645PubMedCrossRef
28.
Zurück zum Zitat Mazerbourg S, Callebaut I, Zapf J, Mohan S, Overgaard M, Monget P (2004) Up date on IGFBP-4: regulation of IGFBP-4 levels and functions, in vitro and in vivo. Growth Horm IGF Res 14:71–84PubMedCrossRef Mazerbourg S, Callebaut I, Zapf J, Mohan S, Overgaard M, Monget P (2004) Up date on IGFBP-4: regulation of IGFBP-4 levels and functions, in vitro and in vivo. Growth Horm IGF Res 14:71–84PubMedCrossRef
29.
Zurück zum Zitat Miyakoshi M, Qin X, Kasukawa Y, Richman C, Srivastava AK, Baylink DJ, Mohan S (2001) Systemic administration of insulin-like growth factor (IGF)-binding protein4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism. Endocrinology 142:2641–2648PubMedCrossRef Miyakoshi M, Qin X, Kasukawa Y, Richman C, Srivastava AK, Baylink DJ, Mohan S (2001) Systemic administration of insulin-like growth factor (IGF)-binding protein4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism. Endocrinology 142:2641–2648PubMedCrossRef
30.
Zurück zum Zitat Edmondson SR, Russo VC, McFarlane AC, Wraight CJ, Werther GA (1999) Interactions between growth hormone, insulin-like growth factor I, and basic fibroblast growth factor in melanocyte growth. J Clin Endocrinol Metab 84:1638–1644CrossRefPubMed Edmondson SR, Russo VC, McFarlane AC, Wraight CJ, Werther GA (1999) Interactions between growth hormone, insulin-like growth factor I, and basic fibroblast growth factor in melanocyte growth. J Clin Endocrinol Metab 84:1638–1644CrossRefPubMed
31.
Zurück zum Zitat Kummer JL, Zawada WM, Freed CR, Chernausek SD, Heidenreich KA (1996) Insulin-like growth factor binding proteins in fetal rat mesencephalic cultures: regulation by fibroblast growth factor and insulin-like growth factor I. Endocrinology 137:3551–3556CrossRefPubMed Kummer JL, Zawada WM, Freed CR, Chernausek SD, Heidenreich KA (1996) Insulin-like growth factor binding proteins in fetal rat mesencephalic cultures: regulation by fibroblast growth factor and insulin-like growth factor I. Endocrinology 137:3551–3556CrossRefPubMed
32.
Zurück zum Zitat Kitazawa R, Fukase M, Imai Y, Sugimoto T, Kano J, Kaji H, Fujita T (1993) Assessment of lumbar bone mineral density in normal Japanese women. Osteoporos Int 3:S245 Kitazawa R, Fukase M, Imai Y, Sugimoto T, Kano J, Kaji H, Fujita T (1993) Assessment of lumbar bone mineral density in normal Japanese women. Osteoporos Int 3:S245
33.
Zurück zum Zitat Norimatsu H, Mori S, Uesato T, Yoshikawa T, Katsuyama N (1989) Bone mineral density of the spine and proximal femur in normal and osteoporotic subjects in Japan. Bone Miner 5:213–222CrossRefPubMed Norimatsu H, Mori S, Uesato T, Yoshikawa T, Katsuyama N (1989) Bone mineral density of the spine and proximal femur in normal and osteoporotic subjects in Japan. Bone Miner 5:213–222CrossRefPubMed
34.
Zurück zum Zitat Riggs BL, Wahner HW, Seeman E, Offord KP, Dunn WL, Mazess RB, Johnson KA, Melton LJ 3rd (1982) Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest 70:716–723PubMedCrossRef Riggs BL, Wahner HW, Seeman E, Offord KP, Dunn WL, Mazess RB, Johnson KA, Melton LJ 3rd (1982) Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest 70:716–723PubMedCrossRef
35.
Zurück zum Zitat Sugimoto T, Kanbara Y, Shiraishi H, Kawakatsu M, Negishi H, Fukase M, Fujita T, Chihara K, Tsutsumi M (1994) Femoral and spinal bone mineral density in Japanese osteoporotics with hip fracture. Osteoporos Int 4:144–148CrossRefPubMed Sugimoto T, Kanbara Y, Shiraishi H, Kawakatsu M, Negishi H, Fukase M, Fujita T, Chihara K, Tsutsumi M (1994) Femoral and spinal bone mineral density in Japanese osteoporotics with hip fracture. Osteoporos Int 4:144–148CrossRefPubMed
36.
Zurück zum Zitat Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268–1274PubMed Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268–1274PubMed
37.
Zurück zum Zitat Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD (1991) Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 72:367–373PubMedCrossRef Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD (1991) Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 72:367–373PubMedCrossRef
38.
Zurück zum Zitat Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:821–828PubMedCrossRef Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:821–828PubMedCrossRef
39.
Zurück zum Zitat Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443CrossRefPubMed Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443CrossRefPubMed
40.
Zurück zum Zitat Szulc P, Joly-Pharaboz MO, Marchand F, Delmas PD (2004) Insulin-like growth factor I is a determinant of hip bone mineral density in men less than 60 years of age: MINOS study. Calcif Tissue Int 74:322–329CrossRefPubMed Szulc P, Joly-Pharaboz MO, Marchand F, Delmas PD (2004) Insulin-like growth factor I is a determinant of hip bone mineral density in men less than 60 years of age: MINOS study. Calcif Tissue Int 74:322–329CrossRefPubMed
41.
Zurück zum Zitat Krassas GE, Papadopoulou P, Koliakos G, Konstantinidis T, Kalothetou K (2003) Growth hormone, insulin growth factor-1, and IGF binding protein-3 axis relationship with bone mineral density among healthy men. Arch Androl 49:191–199PubMedCrossRef Krassas GE, Papadopoulou P, Koliakos G, Konstantinidis T, Kalothetou K (2003) Growth hormone, insulin growth factor-1, and IGF binding protein-3 axis relationship with bone mineral density among healthy men. Arch Androl 49:191–199PubMedCrossRef
42.
Zurück zum Zitat Gillberg P, Olofsson H, Mallmin H, Blum WF, Ljunghall S, Nilsson AG (2002) Bone mineral density in femoral neck is positively correlated to circulating insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-3 in Swedish men. Calcif Tissue Int 70:22–29CrossRefPubMed Gillberg P, Olofsson H, Mallmin H, Blum WF, Ljunghall S, Nilsson AG (2002) Bone mineral density in femoral neck is positively correlated to circulating insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-3 in Swedish men. Calcif Tissue Int 70:22–29CrossRefPubMed
43.
Zurück zum Zitat Seck T, Scheidt-Nave C, Leidig-Bruckner G, Ziegler R, Pfeilschifter J (2001) Low serum concentrations of insulin-like growth factor I are associated with femoral bone loss in a population-based sample of postmenopausal women. Clin Endocrinol (Oxf) 55:101–106CrossRef Seck T, Scheidt-Nave C, Leidig-Bruckner G, Ziegler R, Pfeilschifter J (2001) Low serum concentrations of insulin-like growth factor I are associated with femoral bone loss in a population-based sample of postmenopausal women. Clin Endocrinol (Oxf) 55:101–106CrossRef
44.
Zurück zum Zitat Kim JG, Shin CS, Choi YM, Moon SY, Kim SY, Lee JY (1999) The relationship among circulating insulin-like growth factor components, biochemical markers of bone turnover and bone mineral density in postmenopausal women under the age of 60. Clin Endocrinol (Oxf) 51:301–307CrossRef Kim JG, Shin CS, Choi YM, Moon SY, Kim SY, Lee JY (1999) The relationship among circulating insulin-like growth factor components, biochemical markers of bone turnover and bone mineral density in postmenopausal women under the age of 60. Clin Endocrinol (Oxf) 51:301–307CrossRef
45.
Zurück zum Zitat Amin S, Riggs BL, Atkinson EJ, Oberg AL, Melton LJ 3rd, Khosla S (2004) A potentially deleterious role of IGFBP-2 on bone density in aging men and women. J Bone Miner Res 19:1075–1083PubMedCrossRef Amin S, Riggs BL, Atkinson EJ, Oberg AL, Melton LJ 3rd, Khosla S (2004) A potentially deleterious role of IGFBP-2 on bone density in aging men and women. J Bone Miner Res 19:1075–1083PubMedCrossRef
46.
Zurück zum Zitat Collins D, Woods A, Herd R, Blake G, Fogelman I, Wheeler M, Swaminathan R (1998) Insulin-like growth factor-I and bone mineral density. Bone 23:13–16CrossRefPubMed Collins D, Woods A, Herd R, Blake G, Fogelman I, Wheeler M, Swaminathan R (1998) Insulin-like growth factor-I and bone mineral density. Bone 23:13–16CrossRefPubMed
47.
Zurück zum Zitat Karasik D, Rosen CJ, Hannan MT, Broe KE, Dawson-Hughes B, Gagnon DR, Wilson PW, Visser M, Langlois JA, Mohan S, Kiel DP (2002) Insulin-like growth factor binding proteins 4 and 5 and bone mineral density in elderly men and women. Calcif Tissue Int 71:323–328CrossRefPubMed Karasik D, Rosen CJ, Hannan MT, Broe KE, Dawson-Hughes B, Gagnon DR, Wilson PW, Visser M, Langlois JA, Mohan S, Kiel DP (2002) Insulin-like growth factor binding proteins 4 and 5 and bone mineral density in elderly men and women. Calcif Tissue Int 71:323–328CrossRefPubMed
48.
Zurück zum Zitat Martini G, Valenti R, Giovani S, Franci B, Campagna S, Nuti R (2001) Influence of insulin-like growth factor-1 and leptin on bone mass in healthy postmenopausal women. Bone 28:113–117CrossRefPubMed Martini G, Valenti R, Giovani S, Franci B, Campagna S, Nuti R (2001) Influence of insulin-like growth factor-1 and leptin on bone mass in healthy postmenopausal women. Bone 28:113–117CrossRefPubMed
Metadaten
Titel
Serum Levels of Insulin-Like Growth Factor (IGF); IGF-Binding Proteins-3, -4, and -5; and Their Relationships to Bone Mineral Density and the Risk of Vertebral Fractures in Postmenopausal Women
verfasst von
T. Yamaguchi
M. Kanatani
M. Yamauchi
H. Kaji
T. Sugishita
D. J. Baylink
S. Mohan
K. Chihara
T. Sugimoto
Publikationsdatum
01.01.2006
Erschienen in
Calcified Tissue International / Ausgabe 1/2006
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-005-0163-z

Weitere Artikel der Ausgabe 1/2006

Calcified Tissue International 1/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.